Cargando…
Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B
Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albrig...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365682/ https://www.ncbi.nlm.nih.gov/pubmed/30703064 http://dx.doi.org/10.1530/EDM-18-0125 |
_version_ | 1783393472286294016 |
---|---|
author | Yavropoulou, Maria P Chronopoulos, Efstathios Trovas, George Avramidis, Emmanouil Elli, Francesca Marta Mantovani, Giovanna Zebekakis, Pantelis Yovos, John G |
author_facet | Yavropoulou, Maria P Chronopoulos, Efstathios Trovas, George Avramidis, Emmanouil Elli, Francesca Marta Mantovani, Giovanna Zebekakis, Pantelis Yovos, John G |
author_sort | Yavropoulou, Maria P |
collection | PubMed |
description | Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albright hereditary osteodystrophy (AHO). We present two cases, a 54- and a 33-year-old male diagnosed with PHP who were referred to us for persistently high levels of serum calcitonin. AHO and multinodular goitre were present in the 54-year-old male, while the second patient was free of skeletal deformities and his thyroid gland was of normal size and without nodular appearance. We performed GNAS molecular analysis (methylation status and copy number analysis by MS-MLPA) in genomic DNA samples for both patients. The analysis revealed a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1, in the patient with the clinical diagnosis of PHP1A. This amino acid change appears to be in accordance with the clinical diagnosis of the patient. The genomic DNA analysis of the second patient revealed the presence of the recurrent 3-kb deletion affecting the imprinting control region localised in the STX16 region associated with the loss of methylation (LOM) at the GNAS A/B differentially methylated region and consistent with the diagnosis of an autosomal dominant form of PHP type 1B (PHP1B). In conclusion, hypercalcitoninaemia may be encountered in PHP1A and PHP1B even in the absence of thyroid pathology. LEARNING POINTS: We describe a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1 as the cause of PHP1A. Hypercalcitoninaemia in PHP1A is considered an associated resistance to calcitonin, as suggested by the generalised impairment of Gsα-mediated hormone signalling. GNAS methylation defects, as in type PHP1B, without thyroid pathology can also present with hypercalcitoninaemia. |
format | Online Article Text |
id | pubmed-6365682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63656822019-02-11 Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B Yavropoulou, Maria P Chronopoulos, Efstathios Trovas, George Avramidis, Emmanouil Elli, Francesca Marta Mantovani, Giovanna Zebekakis, Pantelis Yovos, John G Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albright hereditary osteodystrophy (AHO). We present two cases, a 54- and a 33-year-old male diagnosed with PHP who were referred to us for persistently high levels of serum calcitonin. AHO and multinodular goitre were present in the 54-year-old male, while the second patient was free of skeletal deformities and his thyroid gland was of normal size and without nodular appearance. We performed GNAS molecular analysis (methylation status and copy number analysis by MS-MLPA) in genomic DNA samples for both patients. The analysis revealed a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1, in the patient with the clinical diagnosis of PHP1A. This amino acid change appears to be in accordance with the clinical diagnosis of the patient. The genomic DNA analysis of the second patient revealed the presence of the recurrent 3-kb deletion affecting the imprinting control region localised in the STX16 region associated with the loss of methylation (LOM) at the GNAS A/B differentially methylated region and consistent with the diagnosis of an autosomal dominant form of PHP type 1B (PHP1B). In conclusion, hypercalcitoninaemia may be encountered in PHP1A and PHP1B even in the absence of thyroid pathology. LEARNING POINTS: We describe a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1 as the cause of PHP1A. Hypercalcitoninaemia in PHP1A is considered an associated resistance to calcitonin, as suggested by the generalised impairment of Gsα-mediated hormone signalling. GNAS methylation defects, as in type PHP1B, without thyroid pathology can also present with hypercalcitoninaemia. Bioscientifica Ltd 2019-01-31 /pmc/articles/PMC6365682/ /pubmed/30703064 http://dx.doi.org/10.1530/EDM-18-0125 Text en © 2018 The authors http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) . |
spellingShingle | Insight into Disease Pathogenesis or Mechanism of Therapy Yavropoulou, Maria P Chronopoulos, Efstathios Trovas, George Avramidis, Emmanouil Elli, Francesca Marta Mantovani, Giovanna Zebekakis, Pantelis Yovos, John G Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B |
title | Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B |
title_full | Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B |
title_fullStr | Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B |
title_full_unstemmed | Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B |
title_short | Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B |
title_sort | hypercalcitoninaemia in pseudohypoparathyroidism type 1a and type 1b |
topic | Insight into Disease Pathogenesis or Mechanism of Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365682/ https://www.ncbi.nlm.nih.gov/pubmed/30703064 http://dx.doi.org/10.1530/EDM-18-0125 |
work_keys_str_mv | AT yavropouloumariap hypercalcitoninaemiainpseudohypoparathyroidismtype1aandtype1b AT chronopoulosefstathios hypercalcitoninaemiainpseudohypoparathyroidismtype1aandtype1b AT trovasgeorge hypercalcitoninaemiainpseudohypoparathyroidismtype1aandtype1b AT avramidisemmanouil hypercalcitoninaemiainpseudohypoparathyroidismtype1aandtype1b AT ellifrancescamarta hypercalcitoninaemiainpseudohypoparathyroidismtype1aandtype1b AT mantovanigiovanna hypercalcitoninaemiainpseudohypoparathyroidismtype1aandtype1b AT zebekakispantelis hypercalcitoninaemiainpseudohypoparathyroidismtype1aandtype1b AT yovosjohng hypercalcitoninaemiainpseudohypoparathyroidismtype1aandtype1b |